

Curriculum Vitae

Frauke Stanke PD, Dr. rer. nat.
d.o.b. March 12th, 1970, in Essen, Germany

University Education

2012 Venia Legendi for Molecular Human Genetics, MHH
2000 Dissertation Studies Biochemistry, Dr.rer.nat., MHH
1989–1994 Studies of Biochemistry, Medizinische Hochschule Hannover (MHH)

Scientific Career

Since 2020 spokesperson for the working group BioSysMed (biomolecular systems medicine) of the TMF e.V.
Since 2012 principal investigator within the DZL, BREATH Faculty, disease area cystic fibrosis
Since 2007 delegate for the „Technologie- und Methodenplattform für die vernetzte medizinische Forschung e.V.“ (TMF e.V.)
Since 2007 member of the expert committee Ecorn-CF (European Centres of Reference Network for Cystic Fibrosis) funded 2007-2010 by the European Union
2006-2009 member of EuroCareCF (Coordination Action for Research in Cystic Fibrosis) funded by the 6th European Framework program

Awards and Honors

2013 Adolf-Windorfer-Preis 2013 awarded by the Mukoviszidose e.V.

Citation Record

Total citations: 2234; h-index: 22; h-index since 2017: 13 (Google Scholar October 6th, 2022)

Top-10 selected Publications

Dunsche I, Raddatz EL, Ismer H, Hedtfeld S, Tamm S, Moser S, Kontsendorn J, Tümmler B, Janciauskiene S, Dittrich A-M, **Stanke F**. Analysis of cystic fibrosis patient survival confirms STAT3 as a CF modifying gene with changing impact over time. **Hum Mol Genet.** 2022;ddac221. doi: [10.1093/hmg/ddac221](https://doi.org/10.1093/hmg/ddac221).

Becker T, Pich A, Tamm S, Hedtfeld S, Ibrahim M, Altmüller J, Dalibor N, Toliat MR, Janciauskiene S, Tümmler B, **Stanke F**. Genetic information from discordant sibling pairs points to ESRP2 as a candidate trans-acting regulator of the CF modifier gene SCNN1B. **Sci Rep.** 2020;10:22447. doi: [10.1038/s41598-020-79804-y](https://doi.org/10.1038/s41598-020-79804-y)

Stanke F, Janciauskiene S, Tamm S, Wrenger S, Raddatz EL, Jonigk D, Braubach P. Effect of Alpha-1 Antitrypsin on CFTR Levels in Primary Human Airway Epithelial Cells Grown at the Air-Liquid-Interface. **Molecules.** 2021;26:2639. doi: [10.3390/molecules26092639](https://doi.org/10.3390/molecules26092639)

Nietert MM, Vinhoven L, Auer F, Hafkemeyer S, **Stanke F**. Comprehensive Analysis of Chemical Structures That Have Been Tested as CFTR Activating Substances in a Publicly Available Database CandActCFTR. **Front Pharmacol.** 2021;12:689205. doi: [10.3389/fphar.2021.689205](https://doi.org/10.3389/fphar.2021.689205)

Stanke F, Hector A, Hedtfeld S, Hartl D, Griese M, Tümmler B, Mall MA. An informative intragenic microsatellite marker suggests the IL-1 receptor as a genetic modifier in cystic fibrosis. **Eur Respir J.** 2017;50:1700426. doi: [10.1183/13993003.00426-2017](https://doi.org/10.1183/13993003.00426-2017)

Awah CU, Tamm S, Hedtfeld S, Steinemann D, Tümmler B, Tsiavaliaris G, **Stanke F**. Mechanism of allele specific assembly and disruption of master regulator transcription factor complexes of NF-KBp50, NF-KBp65 and HIF1a on a non-coding FAS SNP. **Biochim Biophys Acta.** 2016;1859:1411–1428. doi: [10.1016/j.bbagr.2016.09.002](https://doi.org/10.1016/j.bbagr.2016.09.002)

Stanke F, van Barneveld A, Hedtfeld S, Wölfl S, Becker T, Tümmler B. The CF-modifying gene EHF promotes p.Phe508del-CFTR residual function by altering protein glycosylation and trafficking in epithelial cells. **Eur J Hum Genet.** 2014;22:660-666. doi: [10.1038/ejhg.2013.209](https://doi.org/10.1038/ejhg.2013.209)

Stanke F, Becker T, Kumar V, Hedtfeld S, Becker C, Cuppens H, Tamm S, Yarden J, Laabs U, Siebert B, Fernandez L, Macek M, Radojkovic D, Ballmann M, Greipel J, Cassiman J-J, Wienker TF, Tümmler B. Genes that determine immunology and inflammation modify the basic defect of impaired ion conductance in cystic fibrosis epithelia. **J Med Genet.** 2011;48:24–31. doi: [10.1136/jmg.2010.080937](https://doi.org/10.1136/jmg.2010.080937);

Stanke F, Ballmann M, Bronsveld I, Dork T, Gallati S, Laabs U, Derichs N, Ritzka M, Posselt H-G, Harms HK, Griese M, Blau H, Mastella G, Bijman J, Veeze H, Tümmler B. Diversity of the basic defect of homozygous CFTR mutation genotypes in humans. **J Med Genet.** 2008;45:47–54. doi: [10.1136/jmg.2007.053561](https://doi.org/10.1136/jmg.2007.053561)

Becker T, Jansen S, Tamm S, Wienker TF, Tümmler B, **Stanke F**. Transmission ratio distortion and maternal effects confound the analysis of modulators of cystic fibrosis disease severity on 19q13. **Eur J Hum Genet.** 2007;15:774–778. doi: [10.1038/sj.ejhg.5201825](https://doi.org/10.1038/sj.ejhg.5201825)